AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11876688 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 641
Study 11876688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 29440670 — intervention group
Group type: EXPERIMENTAL
Intervention: Conserved miRNAs
Number of subjects: 0
Study 29440670 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel miRNAs
Number of subjects: 0
Study 29440670 — intervention group
Group type: EXPERIMENTAL
Intervention: Degradome sequencing
Number of subjects: 0
Study 29440670 — intervention group
Group type: EXPERIMENTAL
Intervention: qRT-PCR analysis
Number of subjects: 0
Study 25826200 — intervention group
Group type: EXPERIMENTAL
Intervention: acting out terminology
Number of subjects: 110
Study 25826200 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical terms
Number of subjects: 110
Study 25826200 — intervention group
Group type: COMPARATOR
Intervention: no-reading control
Number of subjects: 110
Study 23864535 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam 0.5%
Number of subjects: 232
Study 23864535 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam 1.0%
Number of subjects: 232
Study 23864535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 23864535 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (both dosages)
Number of subjects: 232
Study 22789766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 50/25 μg, 100/25 μg, and 200/25 μg, dosed once daily in the morning for 28 days
Number of subjects: 54
Study 22789766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20308818 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at the P6 acupoint
Number of subjects: 80
Study 20308818 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonacupoint site stimulation)
Number of subjects: 80
Study 18534970 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T (Th7-8)
Number of subjects: 54
Study 18534970 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (L3-4)
Number of subjects: 54
Study 18534970 — intervention group
Group type: COMPARATOR
Intervention: Group C (Control)
Number of subjects: 54
Study 15831640 — intervention group
Group type: EXPERIMENTAL
Intervention: glipizide 5 mg/day
Number of subjects: 181
Study 15831640 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 500 mg/day
Number of subjects: 181
Study 15831640 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 181
Study 12182254 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 12 g/tazobactam 1.5 g continuous infusion over 24 hours
Number of subjects: 11
Study 12182254 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 6 g/tazobactam 0.75 g continuous infusion over 24 hours
Number of subjects: 11
Study 12182254 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 3 g/tazobactam 0.375 g q6h for 24 hours
Number of subjects: 11
Study 12182254 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 6.75 g continuous infusion over 24 hours
Number of subjects: 11
Study 10564834 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon particulates suspended in PFD
Number of subjects: 12
Study 10564834 — intervention group
Group type: EXPERIMENTAL
Intervention: PFD formulation
Number of subjects: 12
Study 10564834 — intervention group
Group type: COMPARATOR
Intervention: Saline formulation
Number of subjects: 12
Study 8719690 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride 0.5%
Number of subjects: 174
Study 8719690 — intervention group
Group type: COMPARATOR
Intervention: Placebo (apraclonidine's vehicle)
Number of subjects: 174
Study 2110206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine with antiexposure (F)
Number of subjects: 60
Study 2110206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine with exposure (Fe)
Number of subjects: 60
Study 2110206 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with exposure (Pe)
Number of subjects: 60
Study 2110206 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (F)
Number of subjects: 60
Study 2110206 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (Fe)
Number of subjects: 60
Study 2110206 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (F, Fe)
Number of subjects: 60
Study 6777131 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (administered orally in a double-blind fashion)
Number of subjects: 13
Study 6777131 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 13
Study 31253407 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (12 mg/L)
Number of subjects: 405
Study 31253407 — intervention group
Group type: COMPARATOR
Intervention: Low-iron formula (2.3 mg/L)
Number of subjects: 405
Study 30239384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam in combination with haloperidol
Number of subjects: 0
Study 30239384 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (scheduled doses or continuous infusion)
Number of subjects: 0
Study 30239384 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study 25951791 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine and Imipramine
Number of subjects: 166
Study 25951791 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine
Number of subjects: 166
Study 24848008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative passive movement
Number of subjects: 42
Study 24848008 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 21114797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based programme (GRP)
Number of subjects: 42
Study 21114797 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored home-based programme (MHP)
Number of subjects: 42
Study 20048189 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and fluorouracil
Number of subjects: 53
Study 20048189 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 53
Study 20048189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional TP53 mutations
Number of subjects: 53
Study 20048189 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutation
Number of subjects: 53
Study 20048189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional TP53 mutation
Number of subjects: 53
Study 18067659 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus antidepressants (UCandAD)
Number of subjects: 181
Study 18067659 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (UCnoAD)
Number of subjects: 181
Study 16279567 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% olopatadine hydrochloride ophthalmic solution, administered twice daily for 2 weeks in addition to nasal or systemic antiallergy medication.
Number of subjects: 200
Study 16279567 — intervention group
Group type: COMPARATOR
Intervention: No ocular therapy (control group), using only previously prescribed antiallergy medication for 2 weeks.
Number of subjects: 200
Study 11868619 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants exposed to PTP biased against the defendant
Number of subjects: 0
Study 11868619 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicial admonition before and after trial evidence
Number of subjects: 0
Study 11868619 — intervention group
Group type: COMPARATOR
Intervention: Control article
Number of subjects: 0
Study 11868619 — intervention group
Group type: EXPERIMENTAL
Intervention: PTP biased against the plaintiff
Number of subjects: 0
Study 11868619 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicial admonition after trial only or not at all
Number of subjects: 0
Study 11157288 — intervention group
Group type: EXPERIMENTAL
Intervention: System-change training model intervention
Number of subjects: 12
Study 11157288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 9878108 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected versions of passages
Number of subjects: 3
Study 9878108 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected (garden path) versions of passages
Number of subjects: 3
Study 8061842 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg once daily
Number of subjects: 52
Study 8061842 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg once daily
Number of subjects: 52
Study 3141101 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of a fermented milk test product supplying at least 2 X 10(9) live Lactobacillus acidophilus bacteria daily and 6.5% lactulose as substrate for the bacteria.
Number of subjects: 24
Study 3141101 — intervention group
Group type: COMPARATOR
Intervention: Dietary counselling only (Control group).
Number of subjects: 24
Study 766826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexon (polyglycolic acid) sutures
Number of subjects: 51
Study 766826 — intervention group
Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 51
Study 766826 — intervention group
Group type: COMPARATOR
Intervention: Collagen sutures
Number of subjects: 51
Study 31726193 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-focused lifestyle intervention program for 12 months
Number of subjects: 635
Study 31726193 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-to-peer-based lifestyle intervention program for 12 months
Number of subjects: 635
Study 31726193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-adherence participants to the intervention
Number of subjects: 635
Study 31726193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-adherence participants to the intervention
Number of subjects: 635
Study 31726193 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of presence of atherosclerosis
Number of subjects: 635
Study 31726193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 635
Study 31726193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainability of intervention
Number of subjects: 635
Study 30605695 — intervention group
Group type: COMPARATOR
Intervention: Standard bulbar urethroplasty (Group I, n=25)
Number of subjects: 50
Study 30605695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulbar urethroplasty with preservation of bulbospongiosus muscle and nerve (Group II, n=25)
Number of subjects: 50
Study 28279492 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-1 inhibitor reactions
Number of subjects: 12
Study 25289793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate gels (NIT) + UV‐A
Number of subjects: 9
Study 25289793 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT + SHAM
Number of subjects: 9
Study 25289793 — intervention group
Group type: COMPARATOR
Intervention: PLA + UV‐A
Number of subjects: 9
Study 25289793 — intervention group
Group type: COMPARATOR
Intervention: PLA + SHAM
Number of subjects: 9
Study 22520278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis brief intervention (C-O)
Number of subjects: 134
Study 22520278 — intervention group
Group type: EXPERIMENTAL
Intervention: Written cannabis brief intervention (C-W)
Number of subjects: 134
Study 22520278 — intervention group
Group type: COMPARATOR
Intervention: Oral health brief intervention (H-O)
Number of subjects: 134
Study 22520278 — intervention group
Group type: COMPARATOR
Intervention: Written health brief intervention (H-W)
Number of subjects: 134
Study 21597242 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 126
Study 21597242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 126
Study 19339720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 1198
Study 19339720 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 1198
Study 19339720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (wild-type KRAS)
Number of subjects: 1198
Study 16111894 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in shallow water
Number of subjects: 10
Study 16111894 — intervention group
Group type: COMPARATOR
Intervention: Walking on land
Number of subjects: 10
Study 15517844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and clonazepam
Number of subjects: 37
Study 15517844 — intervention group
Group type: COMPARATOR
Intervention: Sertraline and placebo
Number of subjects: 37
Study 11519768 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% BID
Number of subjects: 159
Study 11519768 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol 0.25% BID
Number of subjects: 159
Study 9086143 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD103‐HgR with chloroquine
Number of subjects: 0
Study 9086143 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD103‐HgR with mefloquine
Number of subjects: 0
Study 9086143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a with proguanil
Number of subjects: 0
Study 8441108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered theophylline (aminophylline)
Number of subjects: 21
Study 8441108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2874906 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 1-29 (1 microgram/kg i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Number of subjects: 8
Study 2874906 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (200 micrograms/kg, i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Number of subjects: 8
Study 2874906 — intervention group
Group type: COMPARATOR
Intervention: GRF 1-29 (1 microgram/kg i.v.) without pirenzepine
Number of subjects: 8
Study 2874906 — intervention group
Group type: COMPARATOR
Intervention: TRH (200 micrograms/kg, i.v.) without pirenzepine
Number of subjects: 8
Study 30789857 — intervention group
Group type: EXPERIMENTAL
Intervention: External attentional focus
Number of subjects: 17
Study 30789857 — intervention group
Group type: COMPARATOR
Intervention: Neutral attentional focus
Number of subjects: 17
Study 29427527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidants (vitamins C and E and α‐lipoic acid)
Number of subjects: 21
Study 27861342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (diet and exercise counseling)
Number of subjects: 316
Study 27861342 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 316
Study 24552199 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples-based HIV counseling and testing (CHCT) intervention comprising two group sessions and four couples' counseling sessions.
Number of subjects: 700
Study 24552199 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 700
Study 22615190 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol plus l-carnitine 1 g twice-daily
Number of subjects: 145
Study 22615190 — intervention group
Group type: COMPARATOR
Intervention: cilostazol alone (placebo)
Number of subjects: 145
Study 19880141 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCF + LGG (Nutramigen LGG)
Number of subjects: 30
Study 19880141 — intervention group
Group type: COMPARATOR
Intervention: EHCF - LGG (Nutramigen)
Number of subjects: 30
Study 17702897 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 195
Study 17702897 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment in antithrombotic-treated patients (n = 103)
Number of subjects: 195
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 77465
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up lower endoscopic procedures
Number of subjects: 77465
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up lower endoscopy for larger polyps (> or = 0.5 cm)
Number of subjects: 77465
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up lower endoscopy for smaller polyps (< 0.5 cm)
Number of subjects: 77465
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer detection rates per 1000 screened
Number of subjects: 77465
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced adenoma detection rates per 1000 screened
Number of subjects: 77465
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer or any adenoma detection rates per 1000 screened
Number of subjects: 77465
Study 15998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of colorectal adenocarcinoma at diagnosis
Number of subjects: 77465
Study 12636960 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane condom
Number of subjects: 901
Study 12636960 — intervention group
Group type: COMPARATOR
Intervention: Latex condom
Number of subjects: 901
Study 10496251 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 1.1 mg/d)
Number of subjects: 344
Study 10496251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 10496251 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (mean dose 1.2 mg/d)
Number of subjects: 344
Study 9185259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular anti-snake venom administration as a first aid measure
Number of subjects: 0
Study 9185259 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital management alone
Number of subjects: 0
Study 1684197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0
Study 1684197 — intervention group
Group type: COMPARATOR
Intervention: Parenterally-administered cephalosporin
Number of subjects: 0
Study 4016519 — intervention group
Group type: EXPERIMENTAL
Intervention: Coban bandaging for 3 days
Number of subjects: 154
Study 4016519 — intervention group
Group type: EXPERIMENTAL
Intervention: Coban bandaging for 6 weeks
Number of subjects: 154
Study 4016519 — intervention group
Group type: EXPERIMENTAL
Intervention: Crepe bandaging for 6 weeks
Number of subjects: 154
Study 29102263 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Number of subjects: 847
Study 27267268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20μg once daily
Number of subjects: 437
Study 24272966 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose 2.5g
Number of subjects: 12
Study 24272966 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose 5.0g
Number of subjects: 12
Study 24272966 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose 10.0g
Number of subjects: 12
Study 24272966 — intervention group
Group type: COMPARATOR
Intervention: D-ribose 10.0g with high fat meal (HF)
Number of subjects: 12
Study 24272966 — intervention group
Group type: COMPARATOR
Intervention: D-ribose 10.0g with high carbohydrate meal (HC)
Number of subjects: 12
Study 24272966 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose (all doses)
Number of subjects: 12
Study 22559322 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored exercise intervention for participants with high exercise self-efficacy
Number of subjects: 0
Study 22559322 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored exercise intervention with group-based intervention for participants with low exercise self-efficacy
Number of subjects: 0
Study 22559322 — intervention group
Group type: COMPARATOR
Intervention: Regular Dutch diabetes care (Control group)
Number of subjects: 0
Study 20682569 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1% nasal drops
Number of subjects: 104
Study 20682569 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Control)
Number of subjects: 104
Study 18078723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine 25 mg
Number of subjects: 11
Study 18078723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine 50 mg
Number of subjects: 11
Study 18078723 — intervention group
Group type: COMPARATOR
Intervention: Intranasal methamphetamine 0 mg (control)
Number of subjects: 11
Study 16365618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient Geriatric Unit (GEMU)
Number of subjects: 1388
Study 16365618 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Geriatric Clinic (GEMC)
Number of subjects: 1388
Study 16365618 — intervention group
Group type: COMPARATOR
Intervention: Usual Inpatient Care (UCIP)
Number of subjects: 1388
Study 16365618 — intervention group
Group type: COMPARATOR
Intervention: Usual Outpatient Care (UCOP)
Number of subjects: 1388
Study 11239552 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg depot) every 28 days for 8 weeks
Number of subjects: 358
Study 11239552 — intervention group
Group type: COMPARATOR
Intervention: Sham depot every 28 days for 8 weeks
Number of subjects: 358
Study 11239552 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg depot)
Number of subjects: 358
Study 11239552 — intervention group
Group type: COMPARATOR
Intervention: Sham depot
Number of subjects: 358
Study 9727569 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate therapy (group A: ritonavir, zidovudine and lamivudine)
Number of subjects: 29
Study 9727569 — intervention group
Group type: COMPARATOR
Intervention: Delayed therapy (group B: ritonavir supplemented by zidovudine and lamivudine on day 21)
Number of subjects: 29
Study 7958383 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin G (4.8 mega units, intramuscularly), oral probenecid (1 g), and clavulanate-potentiated amoxycillin (375 mg tablet, orally)
Number of subjects: 55
Study 7958383 — intervention group
Group type: EXPERIMENTAL
Intervention: Further assessment on day 7 for patients with remaining discharge
Number of subjects: 55
Study 2903812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 0
Study 2903812 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 2903812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31927647 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser (area A)
Number of subjects: 20
Study 31927647 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm) (area C)
Number of subjects: 20
Study 31927647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of fractional CO2 laser and Q-switched Nd:YAG laser (area B)
Number of subjects: 20